Capricor Therapeutics price target raised to $50 from $21 at B. Riley

B. Riley raised the firm’s price target on Capricor Therapeutics (CAPR) to $50 from $21 and keeps a Buy rating on the shares. The clinical data support a higher probability of Deramiocel approval, with statistically significant and clinically meaningful efficacy across primary and key secondary endpoints, positioning it as a potential first disease-modifying therapy for DMD and associated cardiomyopathy with a favorable safety profile, the analyst tells investors in a research note. Updated assumptions reflect a 75% probability of success, approximately $380M in pro forma cash, and $1.1B in risk-adjusted net sales by 2030, with substantial royalty-driven upside for Capricor, the firm says.